CTC CoRE Facility set up in the U.S.

John Wayne Cancer Institute and Clearbridge BioMedics announce partnership to develop Circulating Tumor Cell Centre of Research Excellence in the U.S.

Read the news here


       
Clearbridge BioMedics sets up its U.S. subsidiary, Clearbridge BioMedics Inc.

Read the news here

For all sales or product inquiries within the US, contact us at info@clearbridgebiomedics.com

  Introducing a faster, more
  elegant cell enrichment solution.

   The ClearCell® FX1 System
   Novel platform that empowers a brighter future

Give your patients the
chance for a brighter future.

Introducing the CTChip® FR
Label-free CTC Enrichment for Real-time Insights

Paving the way for
Timely, Tailored,
Treatment

Applications
Fluorescence In Situ Hybridisation (FISH)

EML4-ALK gene rearrangement in a non-small cell lung cancer (NSCLC) CTC that had been isolated with the ClearCell® FX System and analysed by FISH...

Read More
Cell Culture

MCF7 breast cancer cells in culture after isolation using the CTChip® FR1...

Read More
Molecular Analysis

Detection of a KRAS mutation in a CTC- enriched sample that had been isolated using the ClearCell® FX System and analysed by Sanger sequencing...

Read More
Immunofluorescence (IF) / Immunocytochemistry (ICC)

DAPI (in blue), pan-cytokeratin (CK) (in green) and EpCAM (in red) staining of cells isolated using the ClearCell® FX System. CTCs are shown to be CK + and EpCAM...

Read More
Products

ClearCell® FX1 System

Driven by CTChip® FR

The ClearCell® FX1 System, driven by the CTChip® FR, is one of the world's first automated cell retrieval systems that can enrich wholly intact and viable Circulating Tumour Cells (CTCs) from small amounts of blood in a relatively short time.

Combined with the high levels of purity, the CTCs are enriched in suspension, which allows for easy integration with downstream molecular analyses and diagnostic assays. This means that researchers and clinicians can use these insights to provide timely, tailored treatment options.

CTChip® FR


The microfluidic biochip captures CTCs based on inertial characteristics such as size and deformability, relative to other blood components, by using Dean Flow Fractionation (DFF). Through the DFF process, the cells are focused within the microfluidic channels of the CTChip® FR, with larger cells along the inner wall and the smaller cells away from it.

This label-free approach ensures effective, continuous and quick separation while retaining cell viability thus lending itself to a myriad of downstream applications.

Locations
Corporate Offices
Distributors
Contact Us for more information